Watch Ticker

Kiniksa Pharmaceuticals, Ltd. Class A Common Stock

Go to Kiniksa Pharmaceuticals, Ltd. Class A Common Stock Website

$0.00

(%)

Live

Previous Close

Day Range

$ - $

Previous Day Range

$ - $

Market Cap

$1.4 billion USD

Day Vol.

Previous Day Vol.

Currency

USD

Primary Exchange

Nasdaq

Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Zacks Equity Research - Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates

Kiniksa Pharmaceuticals (KNSA) delivered earnings and revenue surprises of -78.57% and 4.05%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Related tickers: KNSA, MYNZ.

Read Full Article

Kiniksa Pharmaceuticals, Ltd. - Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $370 - $390 million –– Abiprubart Phase 2b trial in Sjögren’s Disease planned to initiate in 2H 2024 –– Current operating plan expected to remain cash flow positive on an annual basis – – Conference call and webcast scheduled for 8:30 am ET today –

Related tickers: KNSA.

Read Full Article

Trending Tickers

LASE

XNAS

$2.04

(%)

PACW

XNAS

$7.54

(%)

SMFL

XNAS

$3.58

(%)

XNYS

$69.47

(%)

MLGO

XNAS

$0.00

(%)